Drug Profile
Research programme: peptides - Biolingus
Alternative Names: Project B2 (OPUS/SLIT) - Biolingus; Project B3 (OPUS) - Biolingus; Project B5 (SLIT) - BiolingusLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Biolingus
- Class Antihyperlipidaemics; Antineoplastics; Antirheumatics; Biobetters; Dendritic cell vaccines; Peptides
- Mechanism of Action Immunostimulants; PCSK9 protein inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Hypercholesterolaemia; Rheumatoid arthritis
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in Switzerland (Sublingual)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Hypercholesterolaemia in Switzerland (Sublingual)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Switzerland (Sublingual)